Twist Bioscience (NASDAQ:TWST) Stock: Insider Adam Laponis Sells 2,462 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 2,462 shares of Twist Bioscience stock in a transaction on Friday, October 9th. The shares were sold at an average price of $156.30, for a total value of $384,810.60. Following the completion of the transaction, the chief financial officer owned 98,114 shares in the company, valued at approximately $15,335,218.20. The trade was a 2.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Adam Laponis also recently made the following trade(s):

• On Friday, October 2nd, Adam Laponis sold 8,057 shares of Twist Bioscience stock. The stock was sold at an average price of $188.88, for a total value of $1,521,806.16.

Twist Bioscience Price Performance

Shares of TWST stock opened at $148.16 on Thursday. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $219.71. The company has a market cap of $9.29 billion, a P/E ratio of -66.74 and a beta of 2.19. The business has a fifty day simple moving average of $147.04 and a 200 day simple moving average of $98.93.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same period last year, the business earned $0.33 earnings per share. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. On average, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TWST shares. BWS Financial reaffirmed a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. TD Cowen increased their price objective on shares of Twist Bioscience from $115.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday. Guggenheim increased their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Piper Sandler raised their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. Eight analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $143.67.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of TWST. Western Wealth Management LLC acquired a new stake in Twist Bioscience in the first quarter valued at $31,000. Strs Ohio bought a new position in Twist Bioscience during the 1st quarter worth $33,000. PNC Financial Services Group Inc. lifted its holdings in Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after buying an additional 453 shares during the period. Fifth Third Bancorp acquired a new position in Twist Bioscience during the 1st quarter worth about $54,000. Finally, Allworth Financial LP acquired a new position in Twist Bioscience during the 2nd quarter worth about $62,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.